Search - tctmd.com

Displaying 601 - 620 of 732

Sort: Relevancy | Date

Drug-Eluting Balloons: Novel Technology and Applications

Presentation ACC 2012

Drug-Eluting Balloons: Novel Technology and Applications

Presenter: Sigmund Silber

March 26, 2012

News Conference News ACC 2012

Daily Rivaroxaban as Effective as Enoxaparin for Pulmonary Embolism

March 26, 2012

News Conference News ACC 2012

Coronary CTA Effective, Efficient in Ruling Out Patients With Suspected ACS

March 26, 2012

News Conference News ACC 2012

CORONARY Bypass Shows Similar Results Whether On-Pump or Off

March 26, 2012

Renal Sympathetic Denervation for Treatment of Resistant Hypertension: One-Year Results from the Symplicity HTN-2 Randomized Controlled Trial

Presentation ACC 2012

Renal Sympathetic Denervation for Treatment of Resistant Hypertension: One-Year Results from the Symplicity HTN-2 Randomized Controlled Trial

Presenter: Murray Esler

March 25, 2012

News Conference News ACC 2012

INFUSE-AMI: Bolus Abciximab Works, Thrombus Aspiration Doesn’t for Large STEMI

March 25, 2012

News Conference News ACC 2012

EXOME: New Genetic Sequencing Zeroes in on Clopidogrel Response Variants

March 25, 2012

Effect of Transendocardial Delivery of Autologous Bone Marrow Mononuclear Cells on Functional Capacity, Left Ventricular Function, and Perfusion in Chronic Ischemic Heart Failure: The FOCUS-CCTRN Tria

Presentation ACC 2012

Effect of Transendocardial Delivery of Autologous Bone Marrow Mononuclear Cells on Functional Capacity, Left Ventricular Function, and Perfusion in Chronic Ischemic Heart Failure: The FOCUS-CCTRN Trial

Presenter: Emerson C. Perin

March 25, 2012

News Conference News ACC 2012

CPORT-E: PCI Outcomes Similar Regardless of On-Site Cardiac Surgery

March 25, 2012

News Conference News ACC 2012

Color Coding, Checklists Improve Use of Evidence-Based Strategies for ACS

March 25, 2012

News Conference News ACC 2012

BCIS-1: Long-Term Follow-up Shows Lower Mortality with Elective IABP Therapy

March 25, 2012

News Conference News ACC 2012

Adjunctive Cilostazol Noninferior to Double-Dose Clopidogrel in All-Comer PCI Trial

March 25, 2012

A New Strategy for Discontinuation of Dual Antiplatelet Therapy: Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stent Implantation: RESET Trial

Presentation ACC 2012

A New Strategy for Discontinuation of Dual Antiplatelet Therapy: Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stent Implantation: RESET Trial

Presenter: Myeong-Ki Hong

March 25, 2012

A Double Blind Randomized Study to Evaluate the Efficacy of Bindarit in Preventing Coronary Stent Restenosis

Presentation ACC 2012

A Double Blind Randomized Study to Evaluate the Efficacy of Bindarit in Preventing Coronary Stent Restenosis

Presenter: Antonio Colombo

March 25, 2012

2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study

Presentation ACC 2012

2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study

Presenter: Laura Mauri

March 25, 2012

News Conference News ACC 2012

Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES

March 24, 2012

News Conference News ACC 2012

Stem Cell Therapy Fails to Show Benefit in Chronic Ischemic Heart Failure

March 24, 2012

RESET Study: Pharmacodynamic Effects of Switching Therapy in PCI Patients with High on Treatment Platelet Reactivity and Genotype Variation: High Clopidogrel Dose versus Prasugrel

Presentation ACC 2012

RESET Study: Pharmacodynamic Effects of Switching Therapy in PCI Patients with High on Treatment Platelet Reactivity and Genotype Variation: High Clopidogrel Dose versus Prasugrel

Presenter: Gennaro Sardella

March 24, 2012

News Conference News ACC 2012

Prasugrel Effective in Stable Patients With Poor Response to Clopidogrel

March 24, 2012

News Conference News ACC 2012

New Antiplatelet Agent Vorapaxar Shows Promise, But At the Expense of Bleeding

March 24, 2012

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.